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(health and social care services as well as high public and 
private expenditure).[3] Patient adherence is defined as the 
extent to which a person’s behavior, (taking medication, 
following a diet, or executing lifestyle changes) 
corresponds with agreed recommendations from a health 
care provider. Polypharmacy and patient adherence and 
the importance (Scottish Polypharmacy 2015 guidance. 
Model of  care group, Scottish Government 2015. http://
www.polypharmacy.scot.nhs.uk/) to involve patients and 
families with regard to goal setting are problems that 
patients with multimorbidity are facing.[4]
More specifically polypharmacy is associated with several 
risks, including adverse drug reactions, risk of medication 
and disease interactions, and inappropriate dosing and 
adherence. On the other hand, patients could benefit 
from multiple medications if properly addressed when 
medications are combined to cure, slow the progression 
or reduce the symptoms of the diseases.[5]
As the consequence of morbidity, polypharmacy is associated 
with age and poor self-rated health.[6] Furthermore, many 
patients with multi‑morbidity experience difficulty in 
following (agreed upon) treatment recommendations. 
According to the WHO, only 50% of patients are adherent 
to long-term therapy for chronic illnesses.[7] Consequently, 
if patient complexity can be challenging when addressing 
treatment goals for one condition, it will become ever 
more complex when attempting to prioritize treatment 
INTRODUCTION
Due to population aging, increase in chronic disease and 
increased life expectancy, the number of  people living 
with more than one chronic condition is increasing. It is 
estimated that 50 million European citizens suffer from 
multimorbidity (http://ec.europa.eu/health/ageing/
docs/ev_20151007_frep_en.pdf). Among people over the 
age of  65, about 65% have multiple chronic diseases; for 
individuals aged 85+ multiple chronic diseases’ incidence 
is estimated at 85%.[1] Therefore, the number of  people 
living with multimorbidity in the Europe is expected to 
increase further.
Multimorbidity (living with two or more medical 
conditions  where one is not necessarily more central 
than the others ‑ https://ec.europa.eu/eip/ageing/
news/conference-which-priorities-european-policy-
multimorbidity-27th-october-organized-european_en) 
has attracted significant attention among policymakers 
and stakeholders, also because adults with multimorbidity 
account for more than two-thirds of  health-care costs.[2] 
Multimorbidity impacts several levels of  civil society: The 
individual (the quality of  life of  patients and their 
families), the quality and organization of  health‑care 
services at a local level and the whole healthcare system 
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targets for multiple conditions.[8] Of course, despite 
the growing number of people with multiple chronic 
conditions, the majority of treatment guidelines focus on 
single disease and rarely address how to optimally integrate 
care for people with multimorbidity.[9] It is clear that still 
there is not sufficient evidence on how to understand 
and deal with multimorbidity patterns (http://ec.europa.
eu/health/ageing/docs/ev_20151007_frep_en.pdf) and 
consequent patients’ behavior toward adherence.
Following the above need, patient adherence to medical 
plans represents a focus of the European Innovation 
Partnership on Active and Healthy Ageing (https://
ec.europa.eu/eip/ageing/), originally set up by European 
Commission. A clear reflection of this fact is the 
foundation of Action Group (AG) A1 “Prescription and 
Adherence to Medical Plans” (https://ec.europa.eu/
research/innovation-union/pdf/active-healthy-ageing/
a1_achievements_2015.pdf). To address this need AG A1 
adopted an action plan where it identified the most relevant 
areas of activities to address the adherence problem.
ACTIONS OF THE AG A1
In agreement with the overall goals and triple win defined in 
the Strategic Implementation Plan (http://ec.europa.eu/
research/innovationunion/pdf/active-healthy-ageing/
steeringgroup/implementation_plan.pdf#view = fit and 
pagemode = none) (SIP) of the EIP on AHA, the A1 AG 
aims to contribute to the improvement of adherence to 
medical plans and medication at the European level under 
the pillar “Prevention, screening and early diagnosis.”
In particular, the implementation plan called for a set 
of actions to be launched, including the delivery of a 
prescription and adherence action at regional level, as well 
as the development of innovative tools and applications 
to promote health literacy and patient empowerment for 
informed lifestyle choices. To meet the challenges posed 
by the SIP and to boost the effectiveness of their work, 
the AG A1 partners decided to launch a renovated Action 
Plan. The process to gather ideas for the AG A1 renovated 
Action Plan was a well-structured, transparent process that 
was open for every AG A1 member and included several 
steps, namely participatory meetings and on-line surveys. 
During this process stakeholders pointed out that the A1 
vision should be inspired along several themes, e.g.:
•	 “Adopt a holistic approach of adherence”
•	 “Improve communication skills of health professionals 
when dealing with patients and care givers”
•	 “Exploit the potential of information and 
communication technology (ICT) for better 
adherence”
•	 “Disseminate the impact of nonadherence amongst 
policy‑makers”
•	 “Identify and disseminate promising practices”
•	 “Recognise the Pharmacist as a key player in improving 
prescriptions, addressing appropriate polypharmacy 
and supporting adherence to treatments”
•	 “Promoting the role of the pharmacist and 
improvement of the collaborative work between 
healthcare professionals to manage appropriate 
polypharmacy”
•	 “To provide more information aimed at patients on 
pharmacological treatments and chronic diseases 
within the elderly population”
In agreement with the overall goals of the EIP on AHA 
to improve the quality of life, increase the sustainability of 
systems and services and increase the competitiveness of 
the EU economy, the AG A1 [Figure 1] aims to contribute 
to 4 general objectives that are listed below:
•	 General objective 1: Research and advocacy on 
adherence
•	 General objective 2: Reinforce addressing appropriate 
polypharmacy and the role of the pharmacist
•	 General objective 3: Education and empowerment
•	 General objective 4: Exploit the potential of ICT for 
better adherence.
Figure 1 representatives of the A1 AG during the 
European Summit on Innovation for Active and 
Healthy Ageing (https://ec.europa.eu/eip/ageing/
events/european-summit-innovation-active-and-healthy- 
ageing‑transforming‑future‑health‑and‑care_en): 
Transforming the future of Health and Care in Europe.
To support the activities of the A1 group a synergy action 
has also been established. Synergies are thematic working 
groups that are established through a collaborative approach 
and whose interests are cross-cutting to at least two or 
more AGs of the EIP on AHA [Figure 2]. The synergies 
include collaborative work and sprints that were agreed 
on among representatives from the different AGs 
involved. Thus, the “Information technology and 
adherence in aging population with chronic diseases and 
polypharmacy” A1 synergy group has been formed with 
the aim to increase the adherence to treatment of  older 
age adults with chronic diseases and polypharmacy by:
i. Assessing the role of ICT - based solutions such 
as advanced processing of data, decision support 
applications and remote monitoring and consultation 
systems, and by
ii. Implementing tailored ICT-based interventions. We 
expect that the knowledge that will be created will 
support stakeholders to take action in the direction 
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of  improving the quality of  life of  the elderly 
population.
SPECIFIC ACTIONS OF THE A1 SYNERGY 
GROUP AND THE G04‑A1 GROUP
Progress in ICT can facilitate personalized solutions 
for better prevention and engagement in active and 
healthy aging. These advancements supported by 
the digital transformation in health and care and the 
computerization of  medicine can support adherence in 
therapies while empowering the active role of  patients 
in self-managing their diseases. The objectives of  the A1 
synergy and G04-A1 group are to provide an overview 
of  how advanced information technologies of  decision 
support applications, AI and IoT can create a monitoring 
environment that could increase adherence to treatment 
of  older age adults with multiple chronic diseases and 
long-term therapies and appropriate polypharmacy.
Figure 2 shows more than 100 entities (universities, 
Small and Medium Enterprises, Research Centers) are 
participating in the A1 synergy group.
Furthermore, within the framework of their activities 
these groups identified the need to study how integrated 
care systems can support polypharmacy and to understand 
which role integrated care systems, applications and 
monitoring data can play for measurement of adherence 
and of changes in the patient’s behavior and lifestyle.
Integrated care systems have the potential to respond to 
the challenge of providing good qualitative and sustainable 
care to patients with multimorbidity. It is characterized 
as patient-centered, proactive and well-coordinated 
multidisciplinary care, using new technologies to support 
patients’ self-management and adherence to medical 
plans and improve collaboration between caregivers. So 
far, there is insufficient evidence for the beneficial effect 
of integrated care on patient outcomes, patient adherence, 
health-care utilization and costs.[10]
Thus, a scoping study has been initiated to review best 
practices and available literature and to assess whether 
integrated information systems that connect patient with 
health-care professionals can boost adherence to old age 
people in long-term therapies and polypharmacy. The study 
is a working document within the realm of the EIP on AHA 
synergy group with an intention to inform the EU of the 
current status of and gaps in available ICT technology in use.
A scoping study has been adopted because it can provide 
synthesis and analysis of a wide range of research and 
nonresearch material to provide greater conceptual clarity 
about a specific topic or field of evidence[11] and then set 
this within policy and practice contexts.[12]
The scoping study will adopt the methodological 
framework proposed by Arksey and O’Malley[13] since 
this framework provides a supportive foundation for 
scoping study methodology. Recommendations for each 
stage of the framework, followed by considerations for 
the advancement, application, and relevance of scoping 
studies in health research have also been proposed.[14]
The objectives that are set for the scoping study are as 
follows.
GENERAL OBJECTIVES OF THE 
SCOPING STUDY
To increase the adherence to treatment of older age adults 
with chronic multi-diseases and long-term therapies and 
appropriate polypharmacy:
i. Assessing the role of ICT-based solutions in 
understanding adherence behavior and minimizing 
adverse drug reaction accounting for therapeutic 
failure and complications like increase in falls and
ii. Implementing tailored ICT-based interventions
iii. Supporting necessary changes in the direction of 
improving elderlies’ quality of life.
SPECIFIC OBJECTIVES OF THE SCOPING 
STUDY
1. To identify and review a relevant number of ICT 
tools for adherence in long-term therapies and 
polypharmacy and identify the best-in-class.
 The study will review best practices and available 
literature to assess whether ICT-based applications 
that support monitoring of behavior, training, patient 
Figure 1: Representatives of the A1 Action Group during the European 
Summit on Innovation for Active and Healthy Ageing: Transforming 
the future of Health and Care in Europe
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Figure 2: Indicative list of the Entities (universities, SMEs, Research Centers) that are actively participating in the A1 Synergy Group. The A1 
Synergy group has been established to study common ICT and integrated care topics between A1, B3, C2, A2 and A3 action groups. The A1 
Synergy activities aim to harness the collected data from relevant running pilots and from data sets from the above EIP on AHA action groups 
as well as from global best practices and results from specialized workshops. Its general objective is to study if the role of integrated information 
systems that connect patient with health care professionals, pharmacists and other stakeholders can boost adherence to old age people in long-
term therapies and polypharmacy
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empowerment and social interactions can change 
behavior and increase the adherence of older age adults 
to treatment. Results from running pilots and relevant 
data sets from similar studies in EU will be explored.
 The study will consider technological platforms and 
solutions and will examine existing technical solutions 
along with semantic interoperability requirements.
 Furthermore, we will study how advanced ICT 
developments such as decision support applications, 
big data, and others can create a monitoring 
environment that will increase appropriate 
polypharmacy minimizing adverse events like falls. 
The results of this study will help us.
2. To understand the feasibility of  introducing ICT tools 
and applications dedicated to adherence within the realm 
of  integrated information systems that connect patient 
with health care professionals and other stakeholders 
(e.g., patients, family members, health and social carers, 
and members of  municipalities, hospitals, social care 
entities). The role of  pharmacists will be considered.
3. To find evidence where possible of the impact of 
ICT tools for Adherence in Health Services. Impact 
is defined as the effect of the use of ICT tools for 
adherence on financial savings and quality of life.
The study will try to provide a reference of  the 
requirements that an ICT adherence system should 
comply to and provide an architecture design 
methodology and the key technological building blocks 
that should be adopted.
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